(0.07%) 5 051.25 points
(0.04%) 38 485 points
(0.14%) 17 374 points
(-1.03%) $82.00
(0.89%) $1.807
(-1.65%) $2 307.80
(-1.95%) $26.72
(-1.06%) $921.40
(-0.04%) $0.938
(0.21%) $11.01
(-0.10%) $0.809
(-0.11%) $93.31
-0.55% ¥ 3 439.00
Live Chart Being Loaded With Signals
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation...
Stats | |
---|---|
Today's Volume | 94 300.00 |
Average Volume | 117 132 |
Market Cap | 130.23B |
EPS | ¥0 ( 2024-02-05 ) |
Next earnings date | ( ¥0 ) 2024-05-07 |
Last Dividend | ¥75.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 43.81 |
ATR14 | ¥1.789 (0.05%) |
Volume Correlation
Kaken Pharmaceutical Co., Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kaken Pharmaceutical Co., Correlation - Currency/Commodity
Kaken Pharmaceutical Co., Financials
Annual | 2022 |
Revenue: | ¥72.98B |
Gross Profit: | ¥39.56B (54.20 %) |
EPS: | ¥144.79 |
Q3 | 2023 |
Revenue: | ¥18.51B |
Gross Profit: | ¥10.14B (54.76 %) |
EPS: | ¥68.84 |
Q2 | 2023 |
Revenue: | ¥18.02B |
Gross Profit: | ¥9.67B (53.63 %) |
EPS: | ¥41.29 |
Q1 | 2023 |
Revenue: | ¥18.15B |
Gross Profit: | ¥10.06B (55.40 %) |
EPS: | ¥66.98 |
Financial Reports:
No articles found.
Kaken Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥75.00 (N/A) |
¥0 (N/A) |
¥75.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.50 | 2001-03-27 |
Last Dividend | ¥75.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥1 874.70 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.32 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.37 | |
Div. Directional Score | 6.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8524.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7856.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
6999.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6351.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5208.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4312.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3482.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2695.T | Ex Dividend Junior | 2023-10-30 | Annually | 0 | 0.00% | |
9064.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8150.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0411 | 1.500 | 9.18 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0176 | 1.200 | 9.41 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0214 | 1.500 | -0.873 | -1.310 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0229 | -1.500 | 9.62 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 248.72 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.539 | 1.000 | 4.35 | 4.35 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0621 | 1.000 | -0.758 | -0.758 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.429 | 1.000 | 3.17 | 3.17 | [0.2 - 2] |
assetTurnoverTTM | 0.428 | 0.800 | -0.478 | -0.382 | [0.5 - 2] |
Total Score | 10.01 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 43.70 | 1.000 | 5.69 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0214 | 2.50 | -0.561 | -1.310 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.38 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.030 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0763 | 1.000 | -0.592 | 0 | [0.1 - 0.5] |
Total Score | 2.37 |
Kaken Pharmaceutical Co.,
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators